...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Investigative radiology >Evaluation of Gadodiamide Versus Gadobutrol for Contrast-Enhanced MR Imaging in a Rat Brain Glioma Model at 1.5 and 3 T
【24h】

Evaluation of Gadodiamide Versus Gadobutrol for Contrast-Enhanced MR Imaging in a Rat Brain Glioma Model at 1.5 and 3 T

机译：在大鼠脑胶质瘤模型中1.5和3 T加多巴胺与加多布罗对比增强MR成像的评估

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: To compare equivalently-dosed (0.1 mmol/kg) gadobutrol (Ga-dovist) and gadodiamide (Omniscan) in a rat brain glioma model with respect to lesion signal-to-noise (SNR), contrast-to-noise (CNR), and contrast enhancement (CE) at 1.5 and 3 T. Lesion enhancement with standard-dose gadobutrol in scans performed at 1.5 T was also compared with that of half-dose gadobutrol in scans performed at 3 T.Materials and Methods: Fifty-four rats were injected with glioma cells via a plastic brain cannula and divided into 3 groups. In the first group, each animal was studied using gadodiamide and gadobutrol, with 24 hours separating injections. The 2 agents were administered in random order at a dose of 0.1 mmol/kg. Each animal was scanned using a 3 T MR system. The procedure for the second group was similar, but scanning was performed at 1.5 T. For the third group, rats were given standard or half-dose gadobutrol and scanned at 1.5 and 3 T, respectively. For all MR examinations, Tl-weighted images were obtained precontrast and at 1, 3, 5, 7, and 9 minutes postcontrast administration.Results: At 3 T improvements in SNR, CNR, and CE with gadobutrol ranged from 11.8% to 16.0%, 30.5% to 35.4%, and 27.1% to 31.5%, respectively, and at 1.5 T from 7.0% to 11.1%, 27.1% to 35.8%, and 23.8% to 29.5%, respectively. Differences between these parameters with gadobutrol and gadodiamide were statistically significant (P < 0.0001-0.05) at all time points following contrast administration. In group 3, no significant differences in CNR or CE were found between full dose gadobutrol at 1.5 T and half-dose at 3 T, although SNR was significantly greater (28.5%-35.1%; P < 0.0008) at 3 T.Conclusion: Gadobutrol (Gadovist) demonstrates superior lesion enhancement to equivalently-dosed gadodiamide (Omniscan) in the rat brain glioma model. These results are complemented by the improved observed and theoretical safety profile of the first agent, in particular with regard to nephrogenic, systemic fib...
机译：目的：比较大鼠脑胶质瘤模型中等剂量（0.1 mmol / kg）的加多布特罗（Ga-dovist）和加多二酰胺（Omniscan）的病变信噪比（SNR），对比噪声（CNR） ），以及1.5和3 T时的造影剂增强（CE）。在1.5 T时，标准剂量的gadobutrol与3 T时，半剂量gadobutrol的病灶增强也进行了比较。材料和方法：五十-通过塑料大脑套管向四只大鼠注射神经胶质瘤细胞，分为三组。在第一组中，使用加多巴胺和加多巴特罗对每只动物进行研究，并分别注射24小时。两种药物以0.1 mmol / kg的剂量随机给药。使用3 T MR系统扫描每只动物。第二组的程序相似，但是扫描在1.5 T下进行。对于第三组，给大鼠服用标准剂量或半剂量的gadobutrol，分别在1.5 T和3 T下进行扫描。对于所有MR检查，在对比前，对比后1,3、5、7和9分钟获得了T1加权图像。结果：加多巴特罗在3 T时SNR，CNR和CE的改善范围为11.8％至16.0％ 1.5 T时分别为30.5％至35.4％和27.1％至31.5％，在1.5 T下分别为7.0％至11.1％，27.1％至35.8％和23.8％至29.5％。对比剂施用后的所有时间点，加多巴特罗和加多巴胺的这些参数之间的差异在统计学上均具有显着性（P <0.0001-0.05）。在第3组中，尽管在3 T时SNR明显更高（28.5％-35.1％; P <0.0008），但在1.5 T的全剂量gadobutrol和3 T的半剂量gadobutrol之间，CNR或CE均未发现明显差异。 Gadobutrol（Gadovist）在大鼠脑神经胶质瘤模型中显示出比同等剂量的gadodiamide（Omniscan）更好的病灶增强。这些结果得到了第一剂改善的观察到的和理论安全性的补充，特别是在肾源性，全身性纤维化方面。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号